Diovan (Valsartan)- FDA

Diovan (Valsartan)- FDA with

CHICAGO (AP) A major Diovan (Valsartan)- FDA lifts a cloud around Zetia and Vytorin, blockbuster drugs for lowering cholesterol. Doctors have long focused on lowering LDL, or bad cholesterol, to prevent heart disease. Diovan (Valsartan)- FDA like Lipitor, Crestor and Zocor are the main medicines for this, and a lot of research shows they work.

The drug won Food and Drug Administration Diovan (Valsartan)- FDA for lowering LDL, but some studies suggested that might not translate to fewer heart attacks and strokes. One study even questioned whether it raised the chance of cancer.

The new study found that people at high risk of heart problems who took Vytorin for seven years cut their risk of suffering one by 6 percent by 8 percent if they took the drug most faithfully compared to others taking just Zocor.

Vytorin also proved safe. Results were revealed Monday at an American Heart Association conference in Chicago. Neil Stone, a Northwestern University cardiologist.

The 18,000 study participants either had a recent heart attack or worsening chest pain from a severely clogged artery. Half were given Vytorin and the rest were given Zocor alone.

Average Expigment levels went from 95 at the start of the study to 70 with Zocor and 54 with the combo pill Vytorin. About 15 percent of Zocor users had a heart attack versus 13 percent of Diovan (Valsartan)- FDA on Vytorin. Other heart-related problems also were less common with Vytorin.

For every 56 people taking Diovan (Valsartan)- FDA for seven years, one additional heart attack, stroke or heart-related death would be prevented. The study was sponsored m 4 Merck and many doctors involved in it consult for the company or other heart drug makers. Robert Califf said many on it are like him, unable to tolerate a high enough dose of a statin to drop LDL low enough.

The results also boost the prospects for newer drugs many companies are Diovan (Valsartan)- FDA to lower cholesterol even more.

Lori Mosca, a cardiologist from Columbia University and New York-Presbyterian Hospital, and an American Heart spokeswoman. Vytorin is a critical product for both Merck and S-P, providing the greatest sales potential of any product in either companies near-term portfolio, and has already racked up multibillion dollar sales since being launched in the third quarter of 2004.

Part of Diovan (Valsartan)- FDA success as come from data showing that the drug is more potent at lowering blood cholesterol than its big-selling rivals. The data were presented at the International Symposium on Atherosclerosis meeting, held in Rome, Italy.

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app. Subscribe for free Latest jobs View all Medical Advisor Negotiable Diovan (Valsartan)- FDA Analyst Negotiable Regulatory Information Management Analyst Negotiable Procurement Manager Teenagers and parents Compliance Specialist Diovan (Valsartan)- FDA Senior Global Digital Marketing Manager Negotiable What job are you looking for.

Find jobs Job search What Where This field is required. Find jobs Advanced job search Download our apps Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app. Researchers at the American Heart Association meeting on Monday in Chicago presented data from an randomized, double-blind study of 18,144 high-risk patients that found that patients taking Vytorin -- a combination of the cholesterol-lowering statin Zocor plus Zetia, a non-statin -- experienced fewer heart attacks, strokes and repeat hospitalizations than those taking just statins.

The results, which have not yet been peer-reviewed, could Diovan (Valsartan)- FDA alter the landscape for the multi-billion-dollar cholesterol drug industry. The American Heart Association and the American College of Cardiologists currently only recommend statins.

Statins, which lower the amount of LDL or bad cholesterol in the blood, are considered a kind of miracle drug in modern medicine. Among the most widely prescribed in the world, they are often able to lower a person's cholesterol to very low levels with few noticeable side effects.

But they don't work Diovan (Valsartan)- FDA everyone and some can't tolerate a full dose -- they can cause muscle pain, digestive issues and liver damage -- and until now there haven't been any good alternatives. Statins work by reducing the cholesterol made in the liver while Zetia or ezetimibe work by blocking Diovan (Valsartan)- FDA of the cholesterol.

The difference between Diovan (Valsartan)- FDA statin and combination therapy was modest, but Diovan (Valsartan)- FDA. The study, which was funded by Merck and conducted at multiple centers around the world, followed patients for an average of six years after a hospitalization and found a 6. Vytorin has Diovan (Valsartan)- FDA among the most controversial drugs in the cardiovascular world.

After the drug's developers -- Merck and Schering-Plough -- were accused of Diovan (Valsartan)- FDA negative data in 2007-2008, prescriptions fell and the companies' stock prices plunged. Some researchers who were not involved in the study said back then that they wondered Diovan (Valsartan)- FDA Vytorin and Zetia lowered cholesterol but did not reduce heart attacks or strokes.

The results released Monday appeared to indicate that bringing a patient's cholesterol lower does appear to reduce heart incidents. Merck says it plans to submit the data to the Food and Drug Administration in mid-2015 to get approval to market the drug for reducing major cardiovascular events. Gift ArticleToday's HeadlinesThe most important news stories of the day, curated by Post editors and delivered every morning.

Subscribe today ArrowRightThe results, which have not yet been peer-reviewed, could dramatically alter the landscape for the multi-billion-dollar cholesterol drug industry. Story continues below advertisementStatins, which lower the amount of LDL or bad cholesterol in the blood, are considered a kind of miracle drug in modern medicine.

AdvertisementStatins work by reducing the cholesterol made in the liver while Zetia or ezetimibe work by blocking absorption of the cholesterol. Story continues below advertisementVytorin has Diovan (Valsartan)- FDA among the most controversial drugs Diovan (Valsartan)- FDA the cardiovascular world.

AdvertisementSome researchers who were not involved in the study said back then that they wondered whether Vytorin and Zetia lowered cholesterol but did not reduce heart attacks or strokes. GiftOutlineToday's HeadlinesThe most important news stories of the day, curated by Post editors and delivered every morning. Merck said Monday that its cholesterol drug Vytorin was vindicated by a nine-year-long clinical study that aimed to find out if adding a drug that blocked the absorption of cholesterol to a statin, long the gold standard for cholesterol care, would help patients at Diovan (Valsartan)- FDA high risk of heart attack and stroke.

Previous research had raised doubts about Vytorin's effectiveness. In a bit of a surprise, the study, known by the acronym IMPROVE-IT, showed that the drug worked.

Further...

Comments:

29.02.2020 in 23:33 Doramar:
It is a pity, that now I can not express - there is no free time. But I will be released - I will necessarily write that I think.

02.03.2020 in 19:26 Donos:
I join told all above. Let's discuss this question. Here or in PM.

03.03.2020 in 20:42 Yogul:
Excuse for that I interfere � I understand this question. It is possible to discuss.

06.03.2020 in 15:15 Shaktinos:
You have hit the mark. I think, what is it excellent thought.